The present study aims to offer more reliable non-invasive markers for the distinction between pure fatty change and steatohepatitis.
INTRODUCTION
Non-alcoholic fatty liver diseases (NAFLDs) affect 10 to 24 percent of the general population 1 . They encompass a histological spectrum ranging from simple steatosis (i.e., fatty infiltration of the liver) to non-alcoholic steatohepatitis (NASH) (i.e., steatosis with inflammation and hepatocyte necrosis) 2 . Liver steatosis is a benign, nonprogressive condition, in contrast to NASH, which can progress to liver fibrosis, cirrhosis and eventually to hepatocellular carcinoma (HCC) 3 . What exactly triggers the transition of liver steatosis to NASH is still a mystery. The pathogenesis of NASH comprises two steps 4 . First, the healthy liver becomes steatotic, mainly a consequence of peripheral resistance to insulin, whereby the transport of fatty acids from adipose tissue to the liver is increased. Although some protective mechanisms are developed to survive this stress, the fatty liver is in most cases particularly fragile and vulnerable to additional insults 5 . Then, a second step elicited by oxidative stress and inflammatory mediators occurs. This leads to exacerbation of insulin resistance, further oxidative stress, and organelle dysfunction within liver cells, resulting in an inflammatory process, hepatocellular degeneration, and fibrosis 6&7 . The pathogenesis of NAFLDs is still not fully understood, the recognised mechanisms do not fully explain the range of symptoms and physiological processes found in the disease progression. The pathophysiology of NAFLDs should probably be approached as a multifactorial process 8 .
Obesity may be considered one of the most important causal factors for NAFLDs. Adipose tissue participates in regulation of energy balance, glucose and lipid metabolism via the secretion of adipocytokines (i.e. leptin, adiponectin, tumor necrosis factor-α (TNFα) and Interleukin-6 (IL-6) 9 . Leptin, an adipocytederived hormone, regulates food intake and energy homeostasis. Functional impairment of leptin leads to severe obesity and diabetes 10 . TNF-α is synthesized and secreted by visceral adipocytes, stromovascular cells and macrophages. TNF-α mainly acts in an autocrine/paracrine fashion in adipose tissue and it plays a central role in the generation of insulin resistance in rodents. IL-6, on the other hand, is an endocrine cytokine with pleiotropic action ranging from inflammation to host defence (regulation of B and T cell functions) and tissue injury. IL-6 is closely associated with hyperinsulinemia and insulin resistance, and it may also play an important role in the pathogenesis of NASH [6] [7] [8] [9] .
In several stages of NAFLDs, a link between the disease progression and hepatic microvasculature changes can be observed 11 . Angiogenesis, the formation of new blood vessels, is a key mechanism in the pathogenesis of chronic liver diseases, irrespective of their underlying aetiology 12 . Although multiple angiogenic factors have been identified in adipose tissue "i.e. vascular endothelial growth factor" (VEGF), little is known about the interplay between these factors in the adipose tissue environment [13] [14] [15] .
Construction of clearer boundaries between simple steatosis and steatohepatitis is still a clinical challenge that needs further examination. The present study aims to offer more reliable non-invasive markers for the distinction between pure fatty change and steatohepatitis by evaluation the possible role of leptin as a functional link between adipogenesis, angiogenesis and inflammatory status during progression of obesity-related NAFLDs.
MATERIALS AND METHODS

Animals
All animals received human care according to the National Institute of Health guidelines (USA). Sixty male albino rats (2 months old) weighing from (100-150 g) were procured from the central animal facility of the Institute. They were divided in to equal 4 experimental groups (15 rats/group). All rats were provided with commercially available rat normal pellet diet and water ad libitum, prior to the dietary manipulation. Individual body weights and food consumption were recorded weekly.
Chemicals
All chemicals and solvents used in the study were of analytical grade and were obtained either from Sigma Aldrich chemical company unless otherwise mentioned
Diets
Leiber-DeCarli (standard and high fat liquid) diets were used as follows: 1-Standard diet: (35% of energy from fat, 47% from carbohydrates, 18% from protein) 16 . 2-High fat diet: (71% of energy from fat, 11% from carbohydrates, 18% from protein) 17 . The diets were given ad libitum or as twothirds of the amount consumed ad libitum 18 .
Experimental procedure 1-Normal control: animals were fed standard diet for the whole period of experiment. 2-Simple steatosis (SS) group: animals were fed High fat diet (HFD) for 4 weeks. 3-Aggressive steatosis (AS) group: animals were fed HFD for 8 weeks.
4-Non-alcoholic Steatohepatitis (NASH)
Group: animals were fed HFD for 12 weeks.
Liver histopathology
Histological evaluation was performed on a lobe of the liver and portion of specimen was fixed in 10% neutral formalin for 24 hrs then changed to absolute ethanol for dehydration and embedded in paraffin wax. Sections were cut at 4µm in thickness, stained with hematoxylin and eosin for histological examination. Histopathological grading was performed according to the guidelines of Brunt et al. 19 . Histological scoring system for nonalcoholic fatty liver disease (NAFLD) was adopted from Kleiner et al. 20 .
Plasma glucose and insulin levels
Glucose levels were measured using a standard Randox glucose kit. Insulin levels were measured using insulin enzyme immunoassay kit following the instructions of the manufacturer.
Index of insulin resistance
The index of insulin resistance estimated by the homeostasis model assessment insulin resistance (HOMA-IR) was calculated using the following formula 21 
Biochemical Analysis
Liver Function tests (i.e. ALT, AST, GGT), Lipid profile (Total cholesterol, LDL, HDL, Triglycerides) were measured using standard Randox kits. Thiobarbituric acid reactive substances (TBARS) were measured using colorimetric kits (Cayman chemical company, USA), following the instructions of the manufacturer
Enzyme-Linked Immunosorbent Assay (ELISA)
Leptin, VEGF (Bio-Rad company, USA) and TNF-alpha, IL-6 (Abcam, USA) were measured by rat ELISA kits following the instructions of the manufacture.
Western Blotting
Up on determination of individual protein concentrations of the samples using Bradford assay 22 , samples were prepared for loading. Aliquots of frozen hepatic homogenates were routinely examined by sodium dodecyl sulfate polyacrylamide gel electrophoresis followed by immunoblotting. Antibodies for Leptin, VEGF, TNF-alpha, IL-6 and actin were obtained from Abcam, USA.
Statistical analysis
Data were expressed as mean ±SD. Data were analyzed using graph pad Prism statistical software version 5 (referenced for biochemical parameters). Qui square was used in western blot analysis. Statistical differences were calculated with ANOVA test for more than two groups. Pearson's rank correlation coefficient was used for evaluating the correlation between different biochemical variables. p<0.05 was considered as significant.
RESULTS AND DISCUSSION
Results
Initial observations showed significant increase in food intake, final body weights and relative liver weight in HFD groups (P< 0.01) compared to normal control. Blood insulin, glucose levels and HOMA-IR indices were also significantly higher in HFD groups (P< 0.05) in groups II, III and (P< 0.001) in group IV compared to normal control (Table 1) .
Histological examination showed normal hepatic lobular architecture and normal hepatocytes with granulated cytoplasm and small uniform nuclei in group I (Fig. 1A) . On the other hand, group II showed mild steatosis with no evidence of inflammation ( Fig. 1B ). Group III showed massive fat accumulation (both macroand micro-vesicular ( Fig. 1C ). Group IV showed periportal necrosis of the hepatocytes that surround the portal area associated with massive fat accumulation (both macro and microvesicular), ballooning degeneration, Malory's bodies and inflammatory infiltrate of mononuclear inflammatory cells ( Fig. 1D, 1E ). Data are expressed as X -± SD of 10 rats in each group (n=10). Significant difference between groups is analyzed by t-student test, where: (*** P < 0.001, ** P < 0.01, * P < 0.05 compared to normal control). † Relative liver wt= Absolute liver wt/Final body wt. ‡ HOMA-IR= Insulin (mIU/L) x Glucose (mmol/L)/22. Biochemical analysis also showed significant changes in liver enzymes, lipid profile and lipid peroxidation. Group I: did not show any significant changes in the tested parameters. Group II: showed significant changes in GGT (P< 0.05), AST, LDL, HDL (P< 0.01), total cholesterol, triglycerides and TBARS (P< 0.001) except ALT which showed non significant change (p> 0.05). Group III, IV: both showed significant changes (p< 0.001) in all tested parameters ( Table 2) .
ELISA and WB were used to measure serum and tissue levels of leptin, VEGF, TNFα and IL-6. Leptin levels showed significant increase (P< 0.001) in both serum and tissue. VEGF levels also showed significant increase (P< 0.001) in both serum and tissue except in group II which showed non-significant increase (P> 0.05). TNF-α levels showed significant increase (P< 0.05) in group I and (P< 0.001) in groups III and IV. IL-6 levels showed significant increase (P< 0.001) in group IV, (p< 0.05) in group III and non-significant change (P> 0.05) in group II ( Table 3 , Fig. 2 ).
Correlation analysis showed that all tested parameters were positively correlated with histological scoring (NAS) (P< 0.05; r = 0.9749, 0.9890, 0.9909, and 0.9832 for leptin, TNF-α, IL-6 and VEGF respectively (Table 4 ). Histopathological grading for hepatic findings revealed major changes in tested criteria (steatosis grade, affected zone, lobular inflammation grade (LIG), Spotty necrosis/apoptosis (NN/A) and finally cholestasis). Group I: did not show any abnormal findings (no signs for steatosis or inflammation). Group II: showed changes in only 20% of rats manifested by mild steatosis mainly macrovesicular with no sign of inflammation, necrosis/apoptosis or cholestasis. Group III: showed changes in 60% of rats manifested by moderate to severe steatosis with mild inflammation and less common necrosis/apoptosis or cholestasis. Group IV: showed typical signs of NASH in 100% of rats manifested by severe steatosis accompanied with moderate to severe inflammation with more common necrosis/apoptosis or cholestasis. Using NAFLDs scoring system (NAS) for histological scoring, groups I and II showed "NAS ≤ 2" in 100% of rats which corresponds to absence of NASH, group III showed "NAS: 3-4" in 30% of rats which corresponds to uncertain NASH, finally group IV showed "NAS ≥ 5" in 70% of rats which corresponds to definite NASH and "NAS: 3-4" in 30% of rats which corresponds to uncertain NASH (Table 6 ). Data are expressed as X -± SD of 10 rats in each group (n=10). Significant difference between groups is analyzed by t-student test, where: (***P< 0.001, **P< 0.01, *P< 0.05 compared to normal control). TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6; VEGF: Vascular endothelial growth factor. 
AS ( LIG= Lobule Inflammation Grade, SN/A= Spotty necrosis/Apoptosis, Chole= Cholestasis a Steatosis grade: The severity of fatty change determined by estimating the proportion of hepatocytes containing fat droplets (0 (< 5%)= Minimal, 1 (5-33%)= Mild, 2 (33-66%)= Moderate, 3 (> 66%)= Severe, NA = Not applicable). b Affected zones: Zone 1= Peri-portal , Zone 2= mid-zone, Zone 3= centri-lobular. c Type of steatosis: when fat vesicles are large enough to distort the nucleus, the condition is known as macrovesicular steatosis; otherwise, the condition is known as microvesicular. 
Discussion
Understanding the pathogenesis of NAFLD is useful to identify effects and limitations of diagnostic techniques and therapeutic strategies 23 . The great majority of NAFLD occurs in the setting of metabolic syndrome in which insulin resistance plays a key role 24 . It has been estimated that amongst a population of obese⁄diabetic individuals approximately 50-90% will have fatty change, 20-30% will progress to steatohepatitis⁄fibrosis and 2-5% will eventually become cirrhotic 25 . Although fatty change can be reliably diagnosed by non-invasive methods, the distinction between pure fatty change and steatohepatitis can still only be made histologically because of the generally poor correlation between clinical, biochemical and histological findings in NAFLDs 26 . To induce a reliable animal model for NASH, we selected a dietary model developed by Lieber and colleagues that reproduces the dominant clinical features of NASH in rats and mimics the human condition given that NASH is intimately associated with a fat-rich life-style in obese patients [16] [17] [18] .
Histopathological examination, grading and scoring clearly demonstrate that the ingestion of the Lieber liquid high-fat diet during 12 weeks produces all the prominent characteristics of NASH which are consistent with previous reports that illustrated typical features of steatohepatitis including hepatocellular injury (beyond simple fatty change), inflammatory infiltration, hepatocyte ballooning and Mallory's bodies besides other non-typical features like necrosis and cholestasis 27 .
High fat diet is a well characterized rodent model that results in hyperglycaemia, hyperinsulinemia, insulin resistance, defective islet compensation, impaired glucose tolerance and obesity 28 . The adipose tissue cells, called adipocytes are adapted to store large quantities of free fatty acids (FFA) to release them as a fuel on demand. An acquired adipocytokine profile during obesity influences FFA release from adipocytes with the consequent enhancement of lipid delivery to the liver 29 . Under normal conditions in liver cells lipids do not accumulate but rather are transformed into mixed particles like very low density lipoproteins which then can be secreted in the blood stream. The first event in the development of NAFLD is the accumulation of circulating FFA in the liver. They enter into liver cells by simple diffusion and accumulate in high amounts 8 . Whenever a large amount of FFA is present in the liver environment, liver cells increase lipid degradation pathways (lipolysis) but also suppress other pathways including insulin receptor activation, dysfunction of the insulin receptor causes hyperglycemia and secondary hyperinsulinaemia which are common features in the NAFLDs 7&30 .
Our results showed highly significant positive correlation between serum levels of leptin, VEGF, TNF-α and IL-6 versus NAS, a standard scoring system for NAFLDs, which strongly suggests that these parameters can be used to monitor different developmental stages of NAFLDs to limit the use of invasive histopathological diagnostic techniques. There are conflicting reports about the exact role of leptin in the pathogenesis of NAFLD. Some studies demonstrated increased leptin levels in NASH 31&32 , while others found no correlation between serum leptin levels and the development of NASH 33&34 . The principal role of leptin may be to limit the accumulation of fat in non-adipose tissue, and reduce lipotoxicity. By increasing the supply of FFA to the liver, leptin induces dephosphorylation of insulin receptor substrate 1 to prevent hepatic fat accumulation 35 . On the other hand, high levels of serum leptin restrict fat mass expansion via endocrine stimulation of the central negative feedback loop, and paradoxically, leptin might promote adipogenesis through paracrine stimulation of angiogenesis 36 .
Mechanistically, very little is known about how adipokines are differentially regulated during adipose tissue growth. The crosstalk between adipocytes and endothelial cells is mediated by a number of angiogenic regulators, which cooperatively control vessel growth 37 . Interestingly, leptin is also defined as a potent angiogenic factor. The initial finding that endothelial cells express the functional long form of leptin receptor (OB-Rb) has led to the discovery of its angiogenic activity 38 . In addition to its direct angiogenic activity, leptin modulates VEGF-induced vascular activity by synergistically promoting neovascularization in-vivo. Leptin upregulates VEGF mRNA expression via activation of the Jak/Stat3 signaling pathway. Thus leptin may act as an indirect angiogenic factor or a modulator for other known angiogenic factors 39 .
Several proinflammatory cytokines may be pathogenetic in NAFLD. Although several studies have shown that TNF-α is a key factor in the development of NAFLD in both humans and animals, the role of this cytokine remains controversial 40&41 . In the adipose tissue, TNFα acts by repressing genes involved in uptake and storage of non-esterified FFA 42 . These fatty acids are thus readily available to accumulate in non adipose tissues like the liver, increasing the pool of intrahepatic FFA. Increased levels of FFA can also induce TNFα expression within the hepatocytes 43 . Collectively, IL-6 is overexpressed in the adipose tissue of obese patiens 44 . Increased hepatic IL-6 production may play an important role in NASH. Chronically elevated IL-6 levels lead to inappropriate hyperinsulinaemia, impaired insulin-stimulated glucose uptake by the skeletal muscles and marked inflammation in the liver 45&46 . In NAFLDs, increased serum levels of TNFα and IL-6 may originate largely from adipose tissue 47 . In the liver, Kupffer cells are capable of releasing, among other factors, large quantities of TNF-α and IL-6 directly in contact with liver cells influencing hepatic inflammation and fibrogenesis [48] [49] [50] .
Conclusion
The present results reflected a possible interrelation between adipogenesis, angiogenesis and inflammatory status which has an obvious impact on the severity of the underlying obesity related-NAFLDs. This study also highlighted a strong positive correlation between histopathological grading and scoring versus serum levels of our tested parameters (leptin, VEGF, TNF-α, IL-6) which strongly suggest that these parameters, based on their involvement as key players in NAFLDS pathogenesis, may be useful as noninvasive diagnostic tools to differentiate between pure fatty liver and NASH in obese patients.
